The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
TAG, as part of the Save NY Public Health Campaign, called out Governor Cuomo's recently announced Medicaid cuts and other failures to adequately address health and health equity in his January 8, 2020 "State of the State" address.
A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.
TAG’s work in 2019 demonstrated our leadership towards an end to HIV, hepatitis C, and tuberculosis through hard-hitting, science-based activism. Excerpts of the media coverage we received walk you through a remarkable year of TAG’s work.
Treatment Action Group (TAG) applauds progress in New York towards ending HIV as an epidemic, with record decreases in estimated statewide and citywide HIV incidence in 2018. TAG states that accelerating impact at the community level will be critical to reach the Ending the Epidemic 2020 targets.
Vote Your ConSCIENCE: Elevating Health Justice in the 2020 Elections. 2020 marks the eighth U.S. presidential election cycle since Treatment Action Group’s founding in 1992. A hallmark of our activism has been to prepare for each presidential and congressional election cycle strategically, to ensure that whoever is elected, and whoever controls the House and the Senate, is informed about the best scientifically grounded research and policy and research programs.
Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.